Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Clinical Trials
521
Trial Phases
6 Phases
Drug Approvals
9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (417 trials with phase data)• Click on a phase to view related trials
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT07047820
A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT07019064
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT06962800
- Locations
- 🇺🇸
Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac, Michigan, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Nephrotex Research Group, Dallas, Texas, United States
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 255
- Registration Number
- NCT06953583
- Locations
- 🇺🇸
UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California, United States
🇺🇸Norman Fixel Institute for Neurological Diseases UF Health, Gainesville, Florida, United States
🇺🇸USF Health Morsani College of Medicine Department of Neurology, Tampa, Florida, United States
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 454
- Registration Number
- NCT06935357
- Locations
- 🇯🇵
National Hospital Organization Chiba Medical Center Chibahigashi National Hospital, Chiba-shi, Chiba, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan
🇺🇸Applied Research Center of Arkansas, Little Rock, Arkansas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 100
- Next
News
Brenig Therapeutics Appoints New Leadership and Expands Parkinson's Disease Pipeline with NLRP3 Inhibitor Acquisition
Brenig Therapeutics appointed David L. Lucchino as CEO and Tien Dam, M.D., as Chief Medical Officer to advance its neurodegenerative disease pipeline.
Zorevunersen Shows Promising Cognitive and Behavioral Improvements in Dravet Syndrome Phase 3 Trial Analysis
Biogen and Stoke Therapeutics presented new data showing zorevunersen improved cognition and behavior at Week 68 in a Phase 3 dosing regimen analysis for Dravet syndrome patients.
Alzheimer's Drug Market Sees 780% Investment Surge Following Leqembi and Kisunla Approvals
Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments.
Q32 Bio Names Adrien Sipos as Interim CMO to Lead Alopecia Areata Drug Development
Q32 Bio appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to oversee the ongoing SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata treatment.
Biogen Advances Salanersen to Phase 3 Studies for Spinal Muscular Atrophy After Promising Results
Biogen's salanersen (BIIB115/ION306) demonstrated substantial slowing of neurodegeneration and clinically meaningful motor function improvements in children with spinal muscular atrophy previously treated with gene therapy.
CNS Oligonucleotide Licensing Deals Surge 339% to $2.81 Billion in 2024
Licensing agreements for CNS-targeted oligonucleotide therapeutics increased 339% from 2023 to 2024, reaching $2.81 billion in total deal value according to GlobalData's analysis.
Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia
Biogen has initiated the BRAVE study, a global Phase 3 clinical trial evaluating omaveloxolone in children aged 2 to 16 years with Friedreich ataxia.
Maxion Therapeutics Strengthens Leadership with Appointment of Dr. Stefan Härtle as Chief Development Officer
Maxion Therapeutics has appointed Dr. Stefan Härtle as Chief Development Officer, bringing nearly 20 years of pharmaceutical R&D experience to advance the company's KnotBody® platform into clinical trials.
AstraZeneca's Surovatamig Shows Promise as Next-Generation BiTE Therapy for Relapsed/Refractory B-ALL
AstraZeneca's surovatamig demonstrated promising efficacy in the Phase I/II SYRUS trial, achieving complete remission rates of 46%, 58%, and 83% at dose levels 1, 2, and 3 respectively in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Supernus Pharmaceuticals Acquires Sage Therapeutics for $795 Million, Strengthening Neuropsychiatry Portfolio
Supernus Pharmaceuticals announced a definitive agreement to acquire Sage Therapeutics for $8.50 per share upfront plus contingent payments up to $3.50 per share, totaling up to $795 million.